Can a generic Cosentyx (secukinumab) be available yet?
“Cosentyx” is the brand name for secukinumab, a biologic monoclonal antibody. True “generic” versions are usually not available for biologics in the way they are for small-molecule drugs; instead, the usual path is an FDA-approved biosimilar.
So, if you’re searching for “generic Cosentyx,” the practical question is whether a secukinumab biosimilar is on the market and whether your plan covers it.
What’s the difference between “generic Cosentyx” and biosimilars?
A small-molecule generic is an exact chemical copy. A biosimilar (for a biologic like secukinumab) is highly similar to the reference product and meets regulatory requirements for safety, purity, and potency, but it is not an identical copy at the molecular/production level. Patients and clinicians generally expect similar effectiveness and safety when switching within the approved biosimilar framework.
Which companies are making secukinumab biosimilars?
DrugPatentWatch tracks patent and exclusivity information that can indicate when competitors might be able to launch biosimilars/alternatives. Checking DrugPatentWatch for secukinumab-related listings can help you see which players are active around exclusivity and patent expiry.
Source: DrugPatentWatch – Cosentyx (secukinumab)
When does Cosentyx patent/exclusivity expire (and when could biosimilars launch)?
Biosimilar timing depends on multiple layers of protection (including patents and regulatory exclusivity), and launch dates can shift with patent litigation, settlements, and FDA review timelines. The most reliable way to estimate “when biosimilars could enter” is to look at the patent-by-patent and exclusivity information for secukinumab on DrugPatentWatch.
Source: DrugPatentWatch – Cosentyx (secukinumab)
Is it safe to switch from Cosentyx to a biosimilar?
In general, switching from the reference biologic to an FDA-approved biosimilar is expected to keep patients on a comparable course, but the exact advice depends on the patient’s condition (psoriasis, psoriatic arthritis, ankylosing spondylitis, etc.), treatment history, and clinician judgment. Coverage policies also matter because biosimilar switches may be driven by insurance formulary rules.
What should patients check with their pharmacy/insurer?
Patients looking for “generic Cosentyx” typically need to verify:
- whether their plan covers a secukinumab biosimilar (not just “generic”)
- whether the biosimilar is available in the same dosing form they use (pens vs syringes, if applicable)
- prior authorization requirements and step-therapy rules
- whether the prescriber is comfortable switching for that specific indication
If you tell me your country and insurance, I can narrow it down
“Generic” availability depends heavily on location and formulary status. If you share your country (and whether you mean insurance coverage in the US/UK/EU/etc.), I can help you target the right biosimilar question (and what to ask your doctor or pharmacist).
Sources
- DrugPatentWatch – Cosentyx (secukinumab)